

**Recent patent applications in RNA interference**

Patent #	Subject	Assignee	Inventor(s)	Priority application date	Publication date
WO 200512524	A poly(ADP-ribosyl)ation polymerase (PARP) inhibitor of activity of an enzyme that mediates repair of a DNA strand break; useful in treating diseases with gene defects in homologous recombination.	University of Sheffield (UK)	Helleday T	7/25/2003	2/10/2005
WO 200512483	Selectively reducing expression of a vpr coding sequence in a mammalian target cell, comprising introducing into the cell an amount of an RNA interference (RNAi) agent specific for the vpr coding sequence to selectively reduce expression of the coding sequence.	International Therapeutics (Pasadena, CA, USA)	Li Y	8/1/2003	2/10/2005
WO 200511590	Stimulating growth inhibition sensitivity to a cell resistant to growth inhibition by HER2 antagonists, comprising administering PC cell-derived growth factor antagonist to stimulate or restore growth inhibition sensitivity to the cell.	A & G Pharmaceutical (Columbia, MD, USA)	Serrero G	8/1/2003	2/10/2005
WO 200512357	A method for regulating apoptosis in a cell comprising targeting an abnormally or alternatively spliced mRNA, an abnormally or alternatively structured mRNA, or a product of either; useful in the treatment of cancer.	Milmer J	Jiang M, Milmer J	7/31/2003	2/10/2005
WO 200510188	A composition comprising isolated RNA comprising a binding region able to transcriptionally inhibit an expressible gene or a nucleotide sequence able to bind to chromatin within a cell to cause chromatin silencing, where the RNA has less than about 100 nucleotides.	Whitehead Institute for Biomedical Research (Cambridge, MA, USA)	Bartel D, Reinhart BJ	7/21/2003	2/3/2005
WO 200510158	A method of introducing an RNAi agent into a target cell of a subject to produce an RNAi-comprising target cell; useful for treating, particularly, viral-pathogen induced disease conditions, such as HIV-induced disease conditions.	International Therapeutics (Pasadena, CA, USA)	Haffar OK	7/17/2003	2/3/2005
WO 200509346	Treating a disease in a mammal comprising making a polynucleotide-based gene expression inhibitor containing a sequence that is substantially complementary to a nucleic acid sequence in a gene in the mammal, inserting the inhibitor into a vessel of the mammal and delivering the inhibitor to parenchymal cells to inhibit expression of the gene.	Mirus (Madison, WI, USA)	Hagstrom JE, Herweijer H, Lewis DL, Loomis AG, Spencer G, Wolff JA	6/23/2004	2/3/2005
WO 200507850	A method for introducing RNA into a cell involving incubating the cell in the presence of the RNA to be transduced and a cyclodextrin/dendrimer-binding substance; useful for introducing small interfering RNA in a cell, where the transduced RNA is useful for suppressing the expression of a target gene by RNAi.	Kumamoto Technology & Industry Foundation (Kumamoto, Japan)	Arima H, Hirayama F, Uekama K	7/16/2003	1/27/2005
WO 200507196	A nucleic acid-lipid particle comprising a small interfering RNA, cationic lipid, non-cationic lipid and a conjugated lipid that inhibits aggregation of particles.	Protiva Biotherapeutics (Seattle, WA, USA)	Ambegia EG, Heyes J, MacLachlan I	12/11/2003	1/27/2005
WO 200507144	Use of mixed lineage kinase family kinase inhibitor in the manufacture of a medicament for treatment of asthma associated at-risk haplotype for asthma, at-risk haplotype in MAP3K9 gene or increased MLK1 protein expression or activity.	deCODE Genetics (Reykjavik, Iceland)	Gurney ME, Hakonarson H, Halapi E	4/5/2004	1/27/2005

Source: Derwent Information, Alexandria, VA. The status of each application is slightly different from country to country. For further details, contact Derwent Information, 1725 Duke Street, Suite 250, Alexandria, VA 22314. Tel: 1 (800) DERWENT (info.derwent.com).